1513 related articles for article (PubMed ID: 25884928)
1. A combination Alzheimer's therapy targeting BACE1 and neprilysin in 5XFAD transgenic mice.
Devi L; Ohno M
Mol Brain; 2015 Mar; 8():19. PubMed ID: 25884928
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms that lessen benefits of β-secretase reduction in a mouse model of Alzheimer's disease.
Devi L; Ohno M
Transl Psychiatry; 2013 Jul; 3(7):e284. PubMed ID: 23880880
[TBL] [Abstract][Full Text] [Related]
3. Phospho-eIF2α level is important for determining abilities of BACE1 reduction to rescue cholinergic neurodegeneration and memory defects in 5XFAD mice.
Devi L; Ohno M
PLoS One; 2010 Sep; 5(9):e12974. PubMed ID: 20886088
[TBL] [Abstract][Full Text] [Related]
4. Effects of BACE1 haploinsufficiency on APP processing and Aβ concentrations in male and female 5XFAD Alzheimer mice at different disease stages.
Devi L; Ohno M
Neuroscience; 2015 Oct; 307():128-37. PubMed ID: 26314636
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms underlying insulin deficiency-induced acceleration of β-amyloidosis in a mouse model of Alzheimer's disease.
Devi L; Alldred MJ; Ginsberg SD; Ohno M
PLoS One; 2012; 7(3):e32792. PubMed ID: 22403710
[TBL] [Abstract][Full Text] [Related]
6. Genetic reductions of beta-site amyloid precursor protein-cleaving enzyme 1 and amyloid-beta ameliorate impairment of conditioned taste aversion memory in 5XFAD Alzheimer's disease model mice.
Devi L; Ohno M
Eur J Neurosci; 2010 Jan; 31(1):110-8. PubMed ID: 20092558
[TBL] [Abstract][Full Text] [Related]
7. BACE1 elevation engendered by GGA3 deletion increases β-amyloid pathology in association with APP elevation and decreased CHL1 processing in 5XFAD mice.
Kim W; Ma L; Lomoio S; Willen R; Lombardo S; Dong J; Haydon PG; Tesco G
Mol Neurodegener; 2018 Feb; 13(1):6. PubMed ID: 29391027
[TBL] [Abstract][Full Text] [Related]
8. Neprilysin deficiency alters the neuropathological and behavioral phenotype in the 5XFAD mouse model of Alzheimer's disease.
Hüttenrauch M; Baches S; Gerth J; Bayer TA; Weggen S; Wirths O
J Alzheimers Dis; 2015; 44(4):1291-302. PubMed ID: 25408216
[TBL] [Abstract][Full Text] [Related]
9. Partial reduction of BACE1 improves synaptic plasticity, recent and remote memories in Alzheimer's disease transgenic mice.
Kimura R; Devi L; Ohno M
J Neurochem; 2010 Apr; 113(1):248-61. PubMed ID: 20089133
[TBL] [Abstract][Full Text] [Related]
10. Lack of BACE1 S-palmitoylation reduces amyloid burden and mitigates memory deficits in transgenic mouse models of Alzheimer's disease.
Andrew RJ; Fernandez CG; Stanley M; Jiang H; Nguyen P; Rice RC; Buggia-Prévot V; De Rossi P; Vetrivel KS; Lamb R; Argemi A; Allaert ES; Rathbun EM; Krause SV; Wagner SL; Parent AT; Holtzman DM; Thinakaran G
Proc Natl Acad Sci U S A; 2017 Nov; 114(45):E9665-E9674. PubMed ID: 29078331
[TBL] [Abstract][Full Text] [Related]
11. Aβ reduction in BACE1 heterozygous null 5XFAD mice is associated with transgenic APP level.
Sadleir KR; Eimer WA; Cole SL; Vassar R
Mol Neurodegener; 2015 Jan; 10():1. PubMed ID: 25567526
[TBL] [Abstract][Full Text] [Related]
12. 7,8-dihydroxyflavone, a small-molecule TrkB agonist, reverses memory deficits and BACE1 elevation in a mouse model of Alzheimer's disease.
Devi L; Ohno M
Neuropsychopharmacology; 2012 Jan; 37(2):434-44. PubMed ID: 21900882
[TBL] [Abstract][Full Text] [Related]
13. Genetic inhibition of phosphorylation of the translation initiation factor eIF2α does not block Aβ-dependent elevation of BACE1 and APP levels or reduce amyloid pathology in a mouse model of Alzheimer's disease.
Sadleir KR; Eimer WA; Kaufman RJ; Osten P; Vassar R
PLoS One; 2014; 9(7):e101643. PubMed ID: 24992504
[TBL] [Abstract][Full Text] [Related]
14. BACE1 Cleavage Site Selection Critical for Amyloidogenesis and Alzheimer's Pathogenesis.
Zhang S; Wang Z; Cai F; Zhang M; Wu Y; Zhang J; Song W
J Neurosci; 2017 Jul; 37(29):6915-6925. PubMed ID: 28626014
[TBL] [Abstract][Full Text] [Related]
15. GEPT extract reduces Abeta deposition by regulating the balance between production and degradation of Abeta in APPV717I transgenic mice.
Tian J; Shi J; Zhang L; Yin J; Hu Q; Xu Y; Sheng S; Wang P; Ren Y; Wang R; Wang Y
Curr Alzheimer Res; 2009 Apr; 6(2):118-31. PubMed ID: 19355846
[TBL] [Abstract][Full Text] [Related]
16. Relationship between ubiquilin-1 and BACE1 in human Alzheimer's disease and APdE9 transgenic mouse brain and cell-based models.
Natunen T; Takalo M; Kemppainen S; Leskelä S; Marttinen M; Kurkinen KMA; Pursiheimo JP; Sarajärvi T; Viswanathan J; Gabbouj S; Solje E; Tahvanainen E; Pirttimäki T; Kurki M; Paananen J; Rauramaa T; Miettinen P; Mäkinen P; Leinonen V; Soininen H; Airenne K; Tanzi RE; Tanila H; Haapasalo A; Hiltunen M
Neurobiol Dis; 2016 Jan; 85():187-205. PubMed ID: 26563932
[TBL] [Abstract][Full Text] [Related]
17. Beneficial effects of the β-secretase inhibitor GRL-8234 in 5XFAD Alzheimer's transgenic mice lessen during disease progression.
Devi L; Tang J; Ohno M
Curr Alzheimer Res; 2015; 12(1):13-21. PubMed ID: 25523425
[TBL] [Abstract][Full Text] [Related]
18. Regulation of Synaptic Amyloid-β Generation through BACE1 Retrograde Transport in a Mouse Model of Alzheimer's Disease.
Ye X; Feng T; Tammineni P; Chang Q; Jeong YY; Margolis DJ; Cai H; Kusnecov A; Cai Q
J Neurosci; 2017 Mar; 37(10):2639-2655. PubMed ID: 28159908
[TBL] [Abstract][Full Text] [Related]
19. PERK mediates eIF2α phosphorylation responsible for BACE1 elevation, CREB dysfunction and neurodegeneration in a mouse model of Alzheimer's disease.
Devi L; Ohno M
Neurobiol Aging; 2014 Oct; 35(10):2272-81. PubMed ID: 24889041
[TBL] [Abstract][Full Text] [Related]
20. Swedish mutant APP-based BACE1 binding site peptide reduces APP β-cleavage and cerebral Aβ levels in Alzheimer's mice.
Li S; Hou H; Mori T; Sawmiller D; Smith A; Tian J; Wang Y; Giunta B; Sanberg PR; Zhang S; Tan J
Sci Rep; 2015 Jun; 5():11322. PubMed ID: 26091071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
